These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 23711861

  • 1. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
    Takaku Y, Soma T, Nishihara F, Nakagome K, Kobayashi T, Hagiwara K, Kanazawa M, Nagata M.
    Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
    [Abstract] [Full Text] [Related]

  • 2. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W.
    Am J Respir Crit Care Med; 2013 Apr 15; 187(8):804-11. PubMed ID: 23471469
    [Abstract] [Full Text] [Related]

  • 3. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Lenczewska D, Bodzenta-Lukaszyk A.
    Int Arch Allergy Immunol; 2011 Apr 15; 154(1):25-32. PubMed ID: 20664274
    [Abstract] [Full Text] [Related]

  • 4. Salbutamol modulates the balance of Th1 and Th2 cytokines by mononuclear cells from allergic asthmatics.
    Yamaguchi T, Soma T, Takaku Y, Nakagome K, Hagiwara K, Kanazawa M, Nagata M.
    Int Arch Allergy Immunol; 2010 Apr 15; 152 Suppl 1():32-40. PubMed ID: 20523061
    [Abstract] [Full Text] [Related]

  • 5. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
    Tajiri T, Niimi A, Matsumoto H, Ito I, Oguma T, Otsuka K, Takeda T, Nakaji H, Inoue H, Iwata T, Nagasaki T, Kanemitsu Y, Izuhara Y, Mishima M.
    Ann Allergy Asthma Immunol; 2014 Oct 15; 113(4):470-5.e2. PubMed ID: 24994694
    [Abstract] [Full Text] [Related]

  • 6. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
    Djukanović R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV.
    Am J Respir Crit Care Med; 2004 Sep 15; 170(6):583-93. PubMed ID: 15172898
    [Abstract] [Full Text] [Related]

  • 7. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
    Zielen S, Lieb A, De La Motte S, Wagner F, de Monchy J, Fuhr R, Munzu C, Koehne-Voss S, Rivière GJ, Kaiser G, Erpenbeck VJ.
    Int Arch Allergy Immunol; 2013 Sep 15; 160(1):102-10. PubMed ID: 22948442
    [Abstract] [Full Text] [Related]

  • 8. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.
    Hoshino M, Ohtawa J.
    Respiration; 2012 Sep 15; 83(6):520-8. PubMed ID: 22236804
    [Abstract] [Full Text] [Related]

  • 9. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM, QUALITX Study Investigators.
    J Asthma; 2012 Apr 15; 49(3):288-93. PubMed ID: 22356355
    [Abstract] [Full Text] [Related]

  • 10. The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients.
    Pasha MA, Jourd'heuil D, Jourd'heuil F, Mahon L, Romero F, Feustel PJ, Evans M, Smith T, Mitchell J, Gendapodi P, Demeyere-Coursey KC, Townley RG.
    Allergy Asthma Proc; 2014 Apr 15; 35(3):241-9. PubMed ID: 24801467
    [Abstract] [Full Text] [Related]

  • 11. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y, Dobashi K, Fueki N, Fueki M, Okada T, Tomioka S, Makino S, Mori M.
    J Biol Regul Homeost Agents; 2011 Apr 15; 25(2):177-86. PubMed ID: 21880206
    [Abstract] [Full Text] [Related]

  • 12. Inhibitory effects of fluvastatin on cytokine and chemokine production by peripheral blood mononuclear cells in patients with allergic asthma.
    Samson KT, Minoguchi K, Tanaka A, Oda N, Yokoe T, Yamamoto Y, Yamamoto M, Ohta S, Adachi M.
    Clin Exp Allergy; 2006 Apr 15; 36(4):475-82. PubMed ID: 16630152
    [Abstract] [Full Text] [Related]

  • 13. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
    Chen H, Eisner MD, Haselkorn T, Trzaskoma B.
    Respir Med; 2013 Jan 15; 107(1):60-7. PubMed ID: 23083840
    [Abstract] [Full Text] [Related]

  • 14. [Cytokine production by peripheral blood mononuclear cells in bronchial asthma treated with suplatast tosilate].
    Yamasawa H, Oshikawa K, Sugiyama Y.
    Arerugi; 2001 Jun 15; 50(6):513-9. PubMed ID: 11517513
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD, Omalizumab 011 International Study Group.
    Clin Exp Allergy; 2004 Apr 15; 34(4):632-8. PubMed ID: 15080818
    [Abstract] [Full Text] [Related]

  • 17. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.
    Zhu R, Zheng Y, Putnam WS, Visich J, Eisner MD, Matthews JG, Rosen KE, D'Argenio DZ.
    AAPS J; 2013 Apr 15; 15(2):559-70. PubMed ID: 23413101
    [Abstract] [Full Text] [Related]

  • 18. Allergen-induced cytokine production in atopic disease and its relationship to disease severity.
    Leonard C, Tormey V, Burke C, Poulter LW.
    Am J Respir Cell Mol Biol; 1997 Sep 15; 17(3):368-75. PubMed ID: 9308924
    [Abstract] [Full Text] [Related]

  • 19. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
    Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R.
    Respir Med; 2012 Nov 15; 106(11):1494-500. PubMed ID: 22884459
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
    Somerville L, Bardelas J, Viegas A, D'Andrea P, Blogg M, Peachey G.
    Curr Med Res Opin; 2014 Jan 15; 30(1):59-66. PubMed ID: 24028677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.